← Back to home

Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa)

Clinical trials sponsored by Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa), explained in plain language.

Not yet finished but already full! 1

New pill tested as potential lifeline for Tough-to-Treat blood cancers

Disease control Ongoing

This study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…

Phase: PHASE1, PHASE2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control

Last updated Mar 23, 2026 15:19 UTC

Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa)

New pill tested as potential lifeline for Tough-to-Treat blood cancers